Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.71 USD | +1.44% | +7.09% | +38.29% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+38.29% | 1.86B | C | ||
+44.48% | 55.07B | B- | ||
+44.08% | 40.22B | A | ||
-0.86% | 41.79B | B | ||
-7.59% | 28.17B | C | ||
+12.30% | 26.28B | B- | ||
-21.83% | 18.93B | B | ||
+7.15% | 13.03B | B+ | ||
+29.40% | 12.26B | C+ | ||
+25.15% | 12.21B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PTGX Stock
- Ratings Protagonist Therapeutics, Inc.